Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm

Cancer Family

Malignant Neoplasm

CI-CAN-00000025CAExplore in graph →

20,116 active trials259 approved drugs3,741 evidence items

NCIt: C9305
OncoTree: MT
DOID: 162
UMLS CUI: C0006826

Overview
Statistics
Survival
Genomics442
Variants & evidence3741
Drugs424
Trials90685
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,349)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,951–3,975 of 4,349 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
· Nature · 2017 · PMID 28783719 · validated civic_curation pubmed
Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
· Leuk Res · 2014 · PMID 24367893 · validated civic_curation pubmed
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
· Clin Cancer Res · 2015 · PMID 26296355 · validated civic_curation pubmed
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
· EBioMedicine · 2016 · PMID 26870817 · validated civic_curation pubmed
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.
· Br J Cancer · 2010 · PMID 20147967 · validated civic_curation pubmed
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.
· Mol Cancer Ther · 2018 · PMID 29237803 · validated civic_curation pubmed
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
· J Clin Invest · 2009 · PMID 19381019 · validated civic_curation pubmed

Showing 3,951–3,975 of 4,349 publications

← Previous
1
…
158
159
160
…
174
Next →

FGFR3S249C mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells.

· Exp Ther Med · 2019 · PMID 31316618 · validated civic_curation pubmed

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

· Oncogene · 2007 · PMID 17384684 · validated civic_curation pubmed

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

· Nat Commun · 2019 · PMID 31160589 · validated civic_curation pubmed

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

· Oncogene · 2009 · PMID 19749790 · validated civic_curation pubmed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

· Blood · 2004 · PMID 15178581 · validated civic_curation pubmed

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

· Blood · 2017 · PMID 27908881 · validated civic_curation pubmed

Loss of Atrx sensitizes cells to DNA damaging agents through p53-mediated death pathways.

· PLoS One · 2012 · PMID 23284920 · validated civic_curation pubmed

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

· Cell · 2004 · PMID 15035987 · validated civic_curation pubmed

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.

· Am J Cancer Res · 2016 · PMID 27904766 · validated civic_curation pubmed

Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors.

· Cancer Res · 2022 · PMID 35027467 · validated civic_curation pubmed

A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer.

· Cancer Res · 2017 · PMID 28512242 · validated civic_curation pubmed

Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors.

· Cell Cycle · 2014 · PMID 24626198 · validated civic_curation pubmed

High-throughput Phenotyping of Lung Cancer Somatic Mutations.

· Cancer Cell · 2016 · PMID 27478040 · validated civic_curation pubmed

Tyrosine receptor kinase B is a drug target in astrocytomas.

· Neuro Oncol · 2017 · PMID 27402815 · validated civic_curation pubmed

Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene.

· Oncogene · 1997 · PMID 9191060 · validated civic_curation pubmed

Differentiation of NUT midline carcinoma by epigenomic reprogramming.

· Cancer Res · 2011 · PMID 21447744 · validated civic_curation pubmed

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

· Nat Commun · 2019 · PMID 31784538 · validated civic_curation pubmed

Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.

· Cancer Res · 2020 · PMID 32973082 · validated civic_curation pubmed